TeliGen-40/TeliGen-80

Essential HTN. Prevention of CV morbidity & mortality in patients ≥55 yr at high risk of CV disease.

Adult Essential HTN Recommended dose: 40 mg once daily. May be increased to max of 80 mg once daily if target BP is not achieved. Prevention of CV morbidity & mortality Recommended dose: 80 mg once daily. Mild to moderate hepatic impairment Max: 40 mg once daily.

May be taken with or without food.

Hypersensitivity. Biliary obstructive disorders. Concomitant use of aliskiren in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m²). Severe hepatic impairment. Pregnancy (2nd & 3rd trimesters) & lactation.

Hyperkalaemia may occur especially in presence of renal impairment &/or heart failure; monitor serum K. Concomitant use w/ K-sparing diuretics, K supplements, salt substitutes containing K or other medical products that may increase K level (eg, heparin). Symptomatic hypotension in vol &/or Na-depleted patients. Renovascular HTN. Periodically monitor K & creatinine serum levels in patients w/ impaired renal function. Patients w/ recent kidney transplant. Symptomatic hypotension in patients who are vol &/or Na depleted by vigorous diuretic therapy, dietary salt restriction, diarrhea or vomiting. Dual blockade of renin-angiotensin-aldosterone system (eg, adding ACE inhibitor or direct renin-inhibitor aliskiren to AIIA) is not recommended. Other conditions w/ stimulation of renin-angiotensin-aldosterone system. Not recommended in patients w/ primary aldosteronism. Patients suffering from aortic or mitral stenosis or obstructive hypertrophic cardiomyopathy. Increased risk of fatal MI & unexpected CV death in diabetic patients w/ additional CV risk ie, patients w/ DM & coexistent CAD. Undergo appropriate diagnostic evaluation (eg, exercise stress testing) to detect & treat CAD before initiating treatment. Less effective in lowering BP in Black people. Possible MI or stroke in patients w/ ischaemic cardiopathy or CV disease due to excessive reduction of BP. Mild to moderate hepatic impairment. Not recommended during 1st trimester of pregnancy. Childn <18 yr.

UTI (including cystitis), URTI, sepsis; anaemia, eosinophilia, thrombocytopenia; anaphylactic reaction, hypersensitivity; hyperkalaemia, hypoglycaemia (in diabetic patients); anxiety, insomnia, depression; syncope; visual disturbance; vertigo; bradycardia, tachycardia; hypotension, orthostatic hypotension; dyspnoea; abdominal pain, diarrhea, dry mouth, dyspepsia, flatulence, stomach discomfort, vomiting; abnormal hepatic function/liver disorder; pruritus, hyperhidrosis, rash, angioedema, eczema, erythema, urticaria, drug eruption, toxic skin eruption; back pain, muscle spasms (leg cramps), myalgia, arthralgia, pain in extremity (leg pain), tendon pain (tendinitis like symptoms); renal impairment including acute renal failure; chest pain, flu-like illness, asthenia (weakness); increased blood creatinine, blood uric acid, hepatic enzymes & blood creatine phosphokinase, decreased Hb.

May increase hypotensive effect of other antihypertensive agents. Increased median plasma trough conc of digoxin. Increased AUC_0-24 & C_max of ramipril & ramiprilat. Reversible increase in serum conc & toxicity of lithium. Potential acute renal insufficiency in dehydrated patients when concomitantly used w/ NSAIDs (eg, ASA at anti-inflammatory dosage regimens, COX-2 inhibitors & non-selective NSAIDs). Reduced effect by inhibition of vasodilating prostaglandins w/ NSAIDs.

Angiotensin II Antagonists

C09CA07 - telmisartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

Rx